Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Moodys
Colorcon
Medtronic

Last Updated: March 30, 2023

African Regional IP Organization (ARIPO): These 4 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

DrugPatentWatch® Estimated Loss of Exclusivity Dates in African Regional IP Organization (ARIPO)

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "African Regional IP Organization (ARIPO): These 4 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can OMONTYS (peginesatide acetate) generic drug versions launch?

Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,042
Patent Title: Novel peptides that bind to the erythropoietin receptor

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

When can REVLIMID (lenalidomide) generic drug versions launch?

Generic name: lenalidomide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 04, 2023
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,324
Patent Title: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione.

REVLIMID is a drug marketed by Celgene. There are fifteen patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has three hundred and seventy-seven patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Ten suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?

Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,213
Patent Title: Muscarinic acetylcholine receptor antagonists.

Drug Price Trends for INCRUSE ELLIPTA
INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: African Regional IP Organization (ARIPO) Patent 2,204
Patent Title: 4-phenylamino-quinazolin-6-yl-amides.

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
AstraZeneca
Moodys
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.